The top 9 VC investors in US pharma & biotech companies
June 06, 2017
It’s been a good week to be a healthcare investor, with a trio of drug developers moving closer to IPOs. Cancer treatment researcher Aileron Therapeutics has submitted initial paperwork for a $69 million offering, while Dova Pharmaceuticals, a maker of therapies for thrombocytopenia, plans to raise $74.75 million while going public. Cancer drug maker Athenex, meanwhile, has set a price range for its upcoming offering on the NASDAQ, planning to sell 6 million shares for between $11 and $13 apiece.
What about the investment landscape in US pharma & biotech? Since the beginning of 2015, 565 VC investors have participated in at least one such funding, according to the PitchBook Platform, committing nearly $17 billion in total capital across 710 deals. The vast majority of the capital invested (nearly 81%) was for rounds larger than $25 million; about 13% went to fundings between $10 million and $25 million in size.
Here are the top 9 VC investors in US-based pharma & biotech companies since the beginning of 2015, along with deal counts (excluding accelerator rounds):